MET and lung adenocarcinoma: Case Report: Durable partial response to icotinib plus crizotinib in a lung adenocarcinoma patient with double uncommon <i>EGFR</i> G719D/L861Q mutations and an acquired novel <i>CUX1</i>-<i>MET</i> fusion.